RT Journal Article
SR Electronic
T1 SARS-CoV-2 Seroprevalence Among Firefighters in Los Angeles, California
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.06.03.21258299
DO 10.1101/2021.06.03.21258299
A1 Karen Mulligan
A1 Anders H. Berg
A1 Marc Eckstein
A1 Acacia Hori
A1 Anna Rodriguez
A1 Omar Toubat
A1 Neeraj Sood
YR 2021
UL http://medrxiv.org/content/early/2021/06/07/2021.06.03.21258299.abstract
AB Objective We estimate the seroprevalence of SARS-CoV-2 antibodies among firefighters in the Los Angeles, California fire department in October 2020 and compare demographic and contextual factors for seropositivity.Methods We conducted a serologic survey of firefighters in Los Angeles, California, USA, in October 2020. Individuals were classified as seropositive for SARS-CoV-2 if they tested positive for immunoglobulin G, immunoglobulin M, or both. We compared demographic and contextual factors for seropositivity.Results Of 713 participants, 8.9% tested positive for SARS-CoV-2 antibodies. Seropositivity was not associated with gender, age, or race/ethnicity. Furthermore, firefighters who worked in zip codes with lower income or higher share of minority population did not have higher rates of SARS-CoV-2 infection. Seropositivity was highest among firefighters who reported working in the vicinity of Los Angeles International Airport, which had a known outbreak in July 2020.Conclusions Seroprevalence among firefighters was no higher than seroprevalence in the general population, suggesting that workplace safety protocols, such as access to PPE and testing, can mitigate increased risk of infection at work. Workplace safety protocols for firefighters also eliminated differences in disease burden by geography and race/ethnicity observed in the general population.Competing Interest StatementDr. Sood reported receiving funding and in-kind support from Burns and Allen Research Institute at Cedars-Sinai Medical Center, Mayor's Office City of Los Angeles, Rockefeller Foundation, Abbott Diagnostics, and Conrad R. Hilton Foundation for the study.Funding StatementSupported by the Rockefeller Foundation, Conrad N. Hilton Foundation, Burns and Allen Research Institute at Cedars-Sinai Medical Center, and Office of Mayor Eric Garcetti, City of Los Angeles. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the Los Angeles (LA) County Department of Public Health Institutional Review Board.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesIn order to maintain privacy of study participants, data cannot be shared publicly.